Boxer Capital Portfolio
13F Holdings & Position Changes — Last filed Feb 14, 2025
13F Holdings & Position Changes — Last filed Feb 14, 2025
San Diego-based biotech specialist investing across the full drug development lifecycle from preclinical through commercial. Takes concentrated positions with deep scientific due diligence, leveraging proximity to the Southern California biotech cluster.
Boxer Capital is a $0.5B biotech-focused hedge fund managed by Aaron Davis. As of their latest 13F filing (Q4 2024), the fund holds 1 positions worth $0. This quarter they initiated 1 new position and exited 95. Their largest holding is IMA ($0).
Boxer initiated 1 new position this quarter. Portfolio shrank -100.0% to $0. 331 upcoming catalysts across holdings.
Portfolio Value (13F)
$0
Holdings
1
Top 10 Concentration
0%
QoQ Change
-100.0%
Turnover
N/A
Portfolio Value Trend
Be first to know when Boxer Capital files next quarter
Get an email the moment new buys, exits, and conviction changes hit. Free 14-day trial.
| # | Ticker | Company | Change | Value | % of Portfolio | SI % Float ? | Trend |
|---|---|---|---|---|---|---|---|
| 1 | IMA | ImageneBio, Inc. | New | $0 | 0% | — | — |
Track this fund’s next move
13F changes, conviction shifts, and catalyst alerts across all 20 specialist biotech funds — free Monday brief.
No charge for 14 days · Cancel anytime
Boxer Capital held 1 biotech stocks in their 13F portfolio this quarter. Their top positions include IMA. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
Boxer Capital's tracked biotech portfolio is worth $0 across 1 positions, with total assets under management of approximately $0.5B. Portfolio values are based on 13F filings with the SEC.
Boxer Capital initiated 1 new position this quarter, including IMA. They also increased 0 existing positions.
Boxer Capital fully exited 95 positions this quarter, including DAWN, HCAT, NKTX, MIST, VERU and 90 more. They also trimmed 0 existing positions.
San Diego-based biotech specialist investing across the full drug development lifecycle from preclinical through commercial. Takes concentrated positions with deep scientific due diligence, leveraging proximity to the Southern California biotech cluster.
Track specialist biotech funds, insider signals, and AI analysis
Start 14-Day Free Trial| Q2 2024 |
| $1.7B |
| 55 |
| +3 |
| -32 |
| -7.7% |
| Q1 2024 | $1.9B | 52 | +8 | -32 | +19.4% |
| Q4 2023 | $1.6B | 43 | +3 | -33 | +5.4% |
| Q3 2023 | $1.5B | 54 | +3 | -19 | -9.5% |
| Q2 2023 | $1.7B | 56 | +5 | -14 | +0.2% |
| Q1 2023 | $1.7B | 52 | +5 | -13 | +4.6% |
| Q4 2022 | $1.6B | 49 | +5 | -11 | +13.5% |
| Q3 2022 | $1.4B | 49 | +4 | -6 | +16.9% |
| Q2 2022 | $1.2B | 50 | +5 | -1 | -19.2% |
| Q1 2022 | $1.5B | 46 | +46 | — | — |